Event details from: All-Atom Simulations of Co-Translational Protein Folding Reveal Functional and Pharmacological Roles of Folding Intermediates

Date
7 May 2026
Time
15:00 – 16:00

Venue

Science Park 904, room D1.114

Abstract

Protein folding has traditionally been viewed as a process in which an unfolded polypeptide chain rapidly and directly reaches a unique native structure. However, growing evidence points to a far richer and more dynamic landscape, where transient intermediate states play key roles. In this seminar, I will discuss how recent advances in physics-based simulation methods for rare molecular transitions now enable accurate prediction of co-translational protein folding pathways. These approaches have revealed unexpected functional, pathological, and pharmacological roles for metastable states that are transiently populated during folding.

In particular, I will describe Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT), a novel therapeutic strategy that exploits small molecules selectively binding to structural pockets accessible only in folding intermediates, as identified through simulations. By stabilizing these intermediates, such molecules prevent completion of the folding process and trigger protein degradation via the cellular quality control machinery.

The ability to pharmacologically target folding intermediates raises the question of whether these states also have physiological roles in protein homeostasis. Combining bioinformatics, atomistic simulations, and biochemical assays, we have found that roughly one-third of proteins in the human proteome contain phosphorylation sites buried in the hydrophobic core of their native structure. While inaccessible to kinases in the folded state, these sites are transiently exposed in long-lived folding intermediates, suggesting a previously unrecognized regulatory layer linking protein function to folding kinetics.

Bio

Dr. Faccioli is associate professor at the Physics Department of Milan-Bicocca University (Italy) and affiliated member of the Italian Institute for Nuclear Physics (INFN). His research interests include cross-disciplinary applications of theoretical physics, artificial intelligence and quantum computing to simulate and investigate dynamics in complex biomolecular systems. He co-founded Sibylla Biotech, a company that exploits a novel paradigm for rational drug discovery called PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediate Targeting), fuelled by our enhanced sampling algorithms for molecular simulations.

Please let Peter Bolhuis (p.g.bolhuis@uva.nl) know if you would like to talk to Dr. Faccioli before or after the seminar.

This lecture is sponsored by the John van Geuns Foundation.